Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AERIE PHARMACEUTICALS INCAERI · Entity 122210 | Director | May 18, 2020 | May 20, 2020 |
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Director | January 19, 2023 | January 23, 2023 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 11, 2019 | June 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AERIE PHARMACEUTICALS INC
Report date May 18, 2020 · Filed May 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,050 |
Reported balance
After 2020-05-18 transaction · row 1
1 source rowRow 1 · 2020-05-18 · Exercise / conversion · Acquired 28,000 · Balance 36,050 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2023-09-12 | Direct | 0 |
Reported balance
After 2020-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-18 · Exercise / conversion · Disposed 28,000 · Balance 0 F1: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is fully vested and exercisable.
Ayala Pharmaceuticals, Inc.
Report date January 19, 2023 · Filed January 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.21 · Expires 2028-03-20 | Direct | 3,279 |
Reported balance
After 2023-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-19 · Grant · Acquired 3,279 · Balance 3,279 F2: Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share. F1: This option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $47.17 · Expires 2030-02-12 | Direct | 2,342 |
Reported balance
After 2023-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-19 · Grant · Acquired 2,342 · Balance 2,342 F3: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share. F1: This option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2031-06-09 | Direct | 1,171 |
Reported balance
After 2023-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-19 · Grant · Acquired 1,171 · Balance 1,171 F4: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share. F1: This option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2032-06-12 | Direct | 1,171 |
Reported balance
After 2023-01-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-19 · Grant · Acquired 1,171 · Balance 1,171 F6: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share. F5: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is fully vested and exercisable.
F2: Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share.
F3: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share.
F4: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share.
F5: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
F6: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 11, 2019 · Filed June 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 17,621 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 17,621 · Balance 17,621 F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Old Ayala, Inc
Report date January 19, 2023 · Filed January 23, 2023
Section 16 reporting ended · disclosed 2023-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2028-03-20 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-19 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.84 · Expires 2030-02-12 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.35 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-19 · Disposition to issuer · Disposed 6,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2032-06-12 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-19 · Disposition to issuer · Disposed 6,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock").
F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option.
F3: This option is fully vested and exercisable.
F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2023 Filed Jan 23, 2023 18:18 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantStock Option · Derivative | 1,171 | Not disclosed Strike: $8.70 | Not disclosed |
DisclosureSEC source: 0001493152-23-002245 · ownership.xml · derivative · entry 4 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common Stock · 1,171 shares Expires 2032-06-12 F6 · price: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share. F5 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:18 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantStock Option · Derivative | 1,171 | Not disclosed Strike: $55.23 | Not disclosed |
DisclosureSEC source: 0001493152-23-002245 · ownership.xml · derivative · entry 3 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common Stock · 1,171 shares Expires 2031-06-09 F4 · price: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:18 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantStock Option · Derivative | 2,342 | Not disclosed Strike: $47.17 | Not disclosed |
DisclosureSEC source: 0001493152-23-002245 · ownership.xml · derivative · entry 2 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,342 Underlying: Common Stock · 2,342 shares Expires 2030-02-12 F3 · price: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:18 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantStock Option · Derivative | 3,279 | Not disclosed Strike: $27.21 | Not disclosed |
DisclosureSEC source: 0001493152-23-002245 · ownership.xml · derivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Underlying: Common Stock · 3,279 shares Expires 2028-03-20 F2 · price: Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:00 UTC | Old Ayala, Inc AYLA · Entity 108681 | Disposition to issuerStock Option (right to buy) · Derivative | 6,250 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0001213900-23-004539 · ownership.xml · derivative · entry 4 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2032-06-12 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F4 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:00 UTC | Old Ayala, Inc AYLA · Entity 108681 | Disposition to issuerStock Option (right to buy) · Derivative | 6,250 | Not disclosed Strike: $10.35 | Not disclosed |
DisclosureSEC source: 0001213900-23-004539 · ownership.xml · derivative · entry 3 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2031-06-09 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:00 UTC | Old Ayala, Inc AYLA · Entity 108681 | Disposition to issuerStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $8.84 | Not disclosed |
DisclosureSEC source: 0001213900-23-004539 · ownership.xml · derivative · entry 2 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2030-02-12 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 21:00 UTC | Old Ayala, Inc AYLA · Entity 108681 | Disposition to issuerStock Option (right to buy) · Derivative | 17,500 | Not disclosed Strike: $5.10 | Not disclosed |
DisclosureSEC source: 0001213900-23-004539 · ownership.xml · derivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2028-03-20 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock") was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 16:15 UTC | Old Ayala, Inc AYLA · Entity 108681 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0000899243-22-022563 · doc4.xml · derivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2032-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:01 UTC | Old Ayala, Inc AYLA · Entity 108681 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $10.35 | $0.00 |
DisclosureSEC source: 0000899243-21-023593 · doc4.xml · derivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2031-06-09 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 10, 2022 or (ii) one day prior to the Company's 2022 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 18:45 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Exercise / conversionStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-20-031023 · doc4.xml · derivative · entry 2 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,000 shares Expires 2023-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 18, 2020 Filed May 20, 2020 18:45 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Exercise / conversionCommon Stock | 28,000 | $3.15 | $88,200.00 |
DisclosureSEC source: 0001209191-20-031023 · doc4.xml · nonDerivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 10:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 17,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036584 · doc4.xml · derivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Underlying: Ordinary Shares · 17,621 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F2 · derivative.expiration_date: Restricted share units were granted on June 11, 2019 and vest on June 11, 2020. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 23, 2019 Filed May 24, 2019 10:11 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $39.44 | $0.00 |
DisclosureSEC source: 0001209191-19-032589 · doc4.xml · derivative · entry 2 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-05-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of May 23, 2019. Read SEC document |
| May 23, 2019 Filed May 24, 2019 10:11 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032589 · doc4.xml · nonDerivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on May 23, 2020. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:06 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $65.15 | $0.00 |
DisclosureSEC source: 0001209191-18-036812 · doc4.xml · derivative · entry 2 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2028-06-07 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 7, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:06 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036812 · doc4.xml · nonDerivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 7, 2019. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 10:49 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036200 · doc4.xml · derivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Underlying: Ordinary Shares · 6,041 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vest on June 5, 2021. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 16:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $52.85 | $0.00 |
DisclosureSEC source: 0001209191-17-038861 · doc4.xml · derivative · entry 2 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-08 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 8, 2017. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 16:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038861 · doc4.xml · nonDerivative · entry 1 GOLDBERG MURRAY A · CIK 0001226435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,550 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 8, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.